We also evaluate the addition of the CDK2 inhibitor, tagtociclib (PF-07104091) (24), to this treatment regimen and assess whether this triple- drug combination results in greater inhibition of tumor growth in the B16F10 mouse model of melanoma. This evidence concerns the gene CDK2 and neoplasm.